Prof. Dr. med. Peter Fasching

Professur für Translationale Frauenheilkunde und Geburtshilfe

Prognosis of Patients with Early Breast Cancer Receiving 5 Years vs 2 Years of Adjuvant Bisphosphonate Treatment: A Phase 3 Randomized Clinical Trial (2021) Friedl TWP, Fehm T, Mueller V, Lichtenegger W, Blohmer J, Lorenz R, Forstbauer H, et al. Journal article AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2021 (2021) Ditsch N, Kolberg-Liedtke C, Friedrich M, Jackisch C, Albert US, Banys-Paluchowski M, Bauerfeind I, et al. Journal article, Review article AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2021 (2021) Thill M, Friedrich M, Kolberg-Liedtke C, Albert US, Banys-Paluchowski M, Bauerfeind I, Blohmer JU, et al. Journal article, Review article Association of genomic variants at PAX8 and PBX2 with cervical cancer risk (2021) Ramachandran D, Wang Y, Schuermann P, Huelse F, Mao Q, Jentschke M, Boehmer G, et al. Journal article Challenges and Opportunities for Real-World Evidence in Metastatic Luminal Breast Cancer (2021) Lüftner D, Hartkopf AD, Lux MP, Overkamp F, Tesch H, Titzmann A, Pöschke P, et al. Journal article, Review article Prenatal alcohol exposure and the facial phenotype in adolescents: A study based on meconium ethyl glucuronide (2021) Maschke J, Roetner J, Goecke T, Fasching P, Beckmann M, Kratz O, Moll G, et al. Journal article Active Participation, Mind–Body Stabilization, and Coping Strategies with Integrative Medicine in Breast Cancer Patients (2021) Theuser AK, Antoniadis S, Langemann H, Wasner S, Grasruck K, Dietzel-Drentwett S, Fasching P, et al. Journal article Cross-Cancer Genome-Wide Association Study of Endometrial Cancer and Epithelial Ovarian Cancer Identifies Genetic Risk Regions Associated with Risk of Both Cancers (2021) Glubb DM, Thompson DJ, Aben KKH, Alsulimani A, Amant F, Annibali D, Attia J, et al. Journal article Reconstructing tumor history in breast cancer: signatures of mutational processes and response to neoadjuvant chemotherapy☆ (2021) Denkert C, Untch M, Benz S, Schneeweiss A, Weber KE, Schmatloch S, Jackisch C, et al. Journal article Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses (2021) Kang EY, Cheasley D, LePage C, Wakefield MJ, da Cunha Torres M, Rowley S, Salazar C, et al. Journal article